14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AIM vs GNPX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Genprex, Inc. (GNPX) captures the overall head-to-head institutional edge over AIM ImmunoTech Inc. (AIM) on higher Unified Composite conviction (42.2/100 HOLD vs. 39.4/100 SELL) after splitting the core matrix 4–4 (led by Profitability & Quality), while AIM wins 3–1 across the 6-pillar growth and valuation breakdown. AIM trades at $0.11 (2.0x Forward P/E, -11724.2% operating margin) versus GNPX at $1.45 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: GNPX earns the overall head-to-head edge with a stronger Unified Composite Score (42.2/100 HOLD vs. AIM 39.4/100 SELL) and -4.68β · 96% Vol risk profile, whereas AIM leads top-line expansion (+4.0% YoY revenue growth, 0.71x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: AIM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1); meanwhile GNPX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AIM vs GNPX. Trailing 12-month operating profitability (AIM -11724.2% vs GNPX 0.0%) and valuation multiples (AIM 2.0x vs GNPX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AIM vs GNPX Key Questions & Quantitative Answers
As of Nov 20, 2026, Genprex, Inc. (GNPX) captures the overall head-to-head institutional edge over AIM ImmunoTech Inc. (AIM) on higher Unified Composite conviction (42.2/100 HOLD vs. 39.4/100 SELL) after splitting the core matrix 4–4 (led by Profitability & Quality), while AIM wins 3–1 across the 6-pillar growth and valuation breakdown. AIM trades at $0.11 (2.0x Forward P/E, -11724.2% operating margin) versus GNPX at $1.45 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: GNPX earns the overall head-to-head edge with a stronger Unified Composite Score (42.2/100 HOLD vs. AIM 39.4/100 SELL) and -4.68β · 96% Vol risk profile, whereas AIM leads top-line expansion (+4.0% YoY revenue growth, 0.71x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AIM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1); meanwhile GNPX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AIM leads the Growth & Scale pillar: AIM posts +4.0% YoY revenue growth and +0.0% YoY earnings growth on $95,000 TTM revenue (-23.2% gross margin, -11724.2% operating margin), compared with GNPX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AIM generates $95,000 in USD-normalized revenue versus N/A for GNPX. In operating R&D and SG&A reinvestment, AIM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GNPX.
AIM screens cheaper on headline valuation multiples. AIM trades at 2.0x Forward P/E, 2.0x Trailing P/E, 0.71x PEG, and 50.4x EV/Revenue (unreported EBITDA margin), whereas GNPX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AIM (-2382.3% ROE) versus GNPX (-233.7% ROE) capital efficiency.
In options market volatility and institutional positioning, AIM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.56β · 76% Vol realized risk). By comparison, GNPX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-4.68β · 96% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.